newsfilter
← Earnings
Earnings Releases·

Precigen — Third Quarter 2026 Earnings Summary

  • Total revenues surged to $74.1 million in Q3 2026 from $2.9 million in the prior-year period, driven by $72.9 million in PAPZIMEOS net product revenue, while the company reported a net income of $35.8 million ($0.10 per diluted share) compared to a net loss of $325.3 million in the same period of 2025.
  • The company achieved positive operating cash flow of $11.9 million in Q3 2026, reaching this milestone a full quarter ahead of previous guidance, with cash, cash equivalents, and investments totaling $51.0 million as of September 30, 2026.
  • Management expects continued revenue momentum as PAPZIMEOS adoption grows, supported by an ongoing redosing clinical trial, pediatric development, and an EMA review of the Marketing Authorization Application for European expansion.
  • R&D expenses decreased 46.4% year-over-year to $6.6 million due to the capitalization of manufacturing costs post-FDA approval, while SG&A expenses declined 6.8% to $22.4 million, reflecting disciplined spending alongside strong commercial uptake.
Company
PRECIGEN INC
Sector
Healthcare
Industry
Biotechnology